2026 Q1 -tulosraportti
76 päivää sitten
‧1 t 6 min
1,73 USD/osake
Irtoamispäivä 14.8.
0,56%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittencheck out nn
Completely deserved that Novo rises 🥳🤩 https://www.wsj.com/health/pharma/in-the-weight-loss-wars-novos-obesity-pill-is-pulling-way-ahead-of-lillys-d6e8ec3c?mod=hp_lead_pos11&fbclid=IwdGRjcATEbyVwZG9mAWZkaWQWUKmFG9eft8dgapVnTy0zlLNK7XDWN2V4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR41JGiXyUQliuN1TaFRFebrLlKg0vIQlHbZF6tGewkxRmJxRMyciTjfwCcvkA_aem_mXarSzudL9y9gtVbYxxAwA “Novo pulls ahead of Lilly in the race for weight loss pills Novo Nordisk has had a significantly better start than Eli Lilly in the US weight loss pill market. Since the launch of the oral Wegovy in January, Novo has achieved about 89 % of prescriptions, while Lilly's competing pill Foundayo (orforglipron), which first came onto the market in April, has achieved approximately 11 %. The article points to several reasons: * Better documented effect. In clinical studies, patients lost an average of 16.6 % of body weight with the Wegovy tablet versus 12.4 % with Lilly's pill. * Doctors already know the Wegovy name because the injectable version has been on the market for a long time. This makes it easier to choose the oral version. * Lilly had a slower market introduction, partly because insurance coverage was established later. The numbers show how big the difference is: * Wegovy tablet: approx. 153,000 prescriptions in one week. * Foundayo: approx. 19,500 prescriptions in the same week. Analysts' assessment Even though Novo has taken a clear lead, several analysts do not believe that the competition is decided. They highlight, among other things, that: * Lilly may have production advantages in the long term. * Foundayo is expected to be launched in several countries in the coming years. * Both companies will invest massively in marketing and expansion of the market for oral obesity treatments. Significance for Novo Nordisk The article emphasizes that the strong start for the Wegovy tablet is important for Novo after a period where investors have been concerned about competition from Lilly and challenges with Novo's next-generation obesity treatments. The strong demand for the tablet can help restore confidence in Novo Nordisk's growth opportunities.”
·7.7.I thought I read about how “unstable” the Eli Lilly stock is and that it will soon become the next Novo etc etc, but I only see it continues to say When do you think we will see a drop in the stock? What is the price in the short and long term? Is it worth holding for the long term?
28.6. · Muokattu😨🥶😷 Dani Blum, NYT, "The Thriving Black Market for a Powerful Weight Loss Drug, NY Times (June 18, 2026) ("People are buying what they believe to be retatrutide from WhatsApp groups, Chinese labs and websites selling it 'for research purposes.'"), https://www.nytimes.com/2026/06/18/well/retatrutide-peptide-weight-loss-black-market.html?smid=url-share . . . . Retatrutide, the most powerful weight-loss drug in development, is not expected to hit the U.S. market before next year, at the earliest. But Adil Kalam, a 37-year-old in Brooklyn, already has 20 vials of it in his freezer. Mr. Kalam used Bitcoin to purchase the drug from an online retailer selling $99 vials labeled “for research purposes only.” His first order arrived in a cardboard box, the vials of powdered medication packaged in bubble wrap. “It didn’t really inspire confidence,” Mr. Kalam admitted. Mr. Kalam and eight of his friends order the drug in bulk. He understands that there is a risk in taking a drug that has not been approved by the Food and Drug Administration. But he didn’t want to wait for the regulatory process to play out if he could take it sooner. Mr. Kalam is tapping into a thriving black market for retatrutide, a peptide medication developed by Eli Lilly. On social media, influencers and medical spas advertise the drug using code words like “ratatouille” for retatrutide or “peps” for peptides to skirt restrictions on advertising drugs online. More dedicated users buy in bulk from China, trading recommendations for sellers over conversations on Reddit, Discord and WhatsApp, and pooling their resources to get third-party testing. . . . . 😨🥶😷
·26.6.Unbelievable how it rises, and if it's pga the European Medicines Agency which has not approved it for cardiovascular diseases, then I soon don't know what, but rise it does, even on bad days
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
76 päivää sitten
‧1 t 6 min
1,73 USD/osake
Irtoamispäivä 14.8.
0,56%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittencheck out nnCompletely deserved that Novo rises 🥳🤩 https://www.wsj.com/health/pharma/in-the-weight-loss-wars-novos-obesity-pill-is-pulling-way-ahead-of-lillys-d6e8ec3c?mod=hp_lead_pos11&fbclid=IwdGRjcATEbyVwZG9mAWZkaWQWUKmFG9eft8dgapVnTy0zlLNK7XDWN2V4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR41JGiXyUQliuN1TaFRFebrLlKg0vIQlHbZF6tGewkxRmJxRMyciTjfwCcvkA_aem_mXarSzudL9y9gtVbYxxAwA “Novo pulls ahead of Lilly in the race for weight loss pills Novo Nordisk has had a significantly better start than Eli Lilly in the US weight loss pill market. Since the launch of the oral Wegovy in January, Novo has achieved about 89 % of prescriptions, while Lilly's competing pill Foundayo (orforglipron), which first came onto the market in April, has achieved approximately 11 %. The article points to several reasons: * Better documented effect. In clinical studies, patients lost an average of 16.6 % of body weight with the Wegovy tablet versus 12.4 % with Lilly's pill. * Doctors already know the Wegovy name because the injectable version has been on the market for a long time. This makes it easier to choose the oral version. * Lilly had a slower market introduction, partly because insurance coverage was established later. The numbers show how big the difference is: * Wegovy tablet: approx. 153,000 prescriptions in one week. * Foundayo: approx. 19,500 prescriptions in the same week. Analysts' assessment Even though Novo has taken a clear lead, several analysts do not believe that the competition is decided. They highlight, among other things, that: * Lilly may have production advantages in the long term. * Foundayo is expected to be launched in several countries in the coming years. * Both companies will invest massively in marketing and expansion of the market for oral obesity treatments. Significance for Novo Nordisk The article emphasizes that the strong start for the Wegovy tablet is important for Novo after a period where investors have been concerned about competition from Lilly and challenges with Novo's next-generation obesity treatments. The strong demand for the tablet can help restore confidence in Novo Nordisk's growth opportunities.”
- ·7.7.I thought I read about how “unstable” the Eli Lilly stock is and that it will soon become the next Novo etc etc, but I only see it continues to say When do you think we will see a drop in the stock? What is the price in the short and long term? Is it worth holding for the long term?
- 28.6. · Muokattu😨🥶😷 Dani Blum, NYT, "The Thriving Black Market for a Powerful Weight Loss Drug, NY Times (June 18, 2026) ("People are buying what they believe to be retatrutide from WhatsApp groups, Chinese labs and websites selling it 'for research purposes.'"), https://www.nytimes.com/2026/06/18/well/retatrutide-peptide-weight-loss-black-market.html?smid=url-share . . . . Retatrutide, the most powerful weight-loss drug in development, is not expected to hit the U.S. market before next year, at the earliest. But Adil Kalam, a 37-year-old in Brooklyn, already has 20 vials of it in his freezer. Mr. Kalam used Bitcoin to purchase the drug from an online retailer selling $99 vials labeled “for research purposes only.” His first order arrived in a cardboard box, the vials of powdered medication packaged in bubble wrap. “It didn’t really inspire confidence,” Mr. Kalam admitted. Mr. Kalam and eight of his friends order the drug in bulk. He understands that there is a risk in taking a drug that has not been approved by the Food and Drug Administration. But he didn’t want to wait for the regulatory process to play out if he could take it sooner. Mr. Kalam is tapping into a thriving black market for retatrutide, a peptide medication developed by Eli Lilly. On social media, influencers and medical spas advertise the drug using code words like “ratatouille” for retatrutide or “peps” for peptides to skirt restrictions on advertising drugs online. More dedicated users buy in bulk from China, trading recommendations for sellers over conversations on Reddit, Discord and WhatsApp, and pooling their resources to get third-party testing. . . . . 😨🥶😷
- ·26.6.Unbelievable how it rises, and if it's pga the European Medicines Agency which has not approved it for cardiovascular diseases, then I soon don't know what, but rise it does, even on bad days
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 |
2026 Q1 -tulosraportti
76 päivää sitten
‧1 t 6 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 |
1,73 USD/osake
Irtoamispäivä 14.8.
0,56%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittencheck out nnCompletely deserved that Novo rises 🥳🤩 https://www.wsj.com/health/pharma/in-the-weight-loss-wars-novos-obesity-pill-is-pulling-way-ahead-of-lillys-d6e8ec3c?mod=hp_lead_pos11&fbclid=IwdGRjcATEbyVwZG9mAWZkaWQWUKmFG9eft8dgapVnTy0zlLNK7XDWN2V4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR41JGiXyUQliuN1TaFRFebrLlKg0vIQlHbZF6tGewkxRmJxRMyciTjfwCcvkA_aem_mXarSzudL9y9gtVbYxxAwA “Novo pulls ahead of Lilly in the race for weight loss pills Novo Nordisk has had a significantly better start than Eli Lilly in the US weight loss pill market. Since the launch of the oral Wegovy in January, Novo has achieved about 89 % of prescriptions, while Lilly's competing pill Foundayo (orforglipron), which first came onto the market in April, has achieved approximately 11 %. The article points to several reasons: * Better documented effect. In clinical studies, patients lost an average of 16.6 % of body weight with the Wegovy tablet versus 12.4 % with Lilly's pill. * Doctors already know the Wegovy name because the injectable version has been on the market for a long time. This makes it easier to choose the oral version. * Lilly had a slower market introduction, partly because insurance coverage was established later. The numbers show how big the difference is: * Wegovy tablet: approx. 153,000 prescriptions in one week. * Foundayo: approx. 19,500 prescriptions in the same week. Analysts' assessment Even though Novo has taken a clear lead, several analysts do not believe that the competition is decided. They highlight, among other things, that: * Lilly may have production advantages in the long term. * Foundayo is expected to be launched in several countries in the coming years. * Both companies will invest massively in marketing and expansion of the market for oral obesity treatments. Significance for Novo Nordisk The article emphasizes that the strong start for the Wegovy tablet is important for Novo after a period where investors have been concerned about competition from Lilly and challenges with Novo's next-generation obesity treatments. The strong demand for the tablet can help restore confidence in Novo Nordisk's growth opportunities.”
- ·7.7.I thought I read about how “unstable” the Eli Lilly stock is and that it will soon become the next Novo etc etc, but I only see it continues to say When do you think we will see a drop in the stock? What is the price in the short and long term? Is it worth holding for the long term?
- 28.6. · Muokattu😨🥶😷 Dani Blum, NYT, "The Thriving Black Market for a Powerful Weight Loss Drug, NY Times (June 18, 2026) ("People are buying what they believe to be retatrutide from WhatsApp groups, Chinese labs and websites selling it 'for research purposes.'"), https://www.nytimes.com/2026/06/18/well/retatrutide-peptide-weight-loss-black-market.html?smid=url-share . . . . Retatrutide, the most powerful weight-loss drug in development, is not expected to hit the U.S. market before next year, at the earliest. But Adil Kalam, a 37-year-old in Brooklyn, already has 20 vials of it in his freezer. Mr. Kalam used Bitcoin to purchase the drug from an online retailer selling $99 vials labeled “for research purposes only.” His first order arrived in a cardboard box, the vials of powdered medication packaged in bubble wrap. “It didn’t really inspire confidence,” Mr. Kalam admitted. Mr. Kalam and eight of his friends order the drug in bulk. He understands that there is a risk in taking a drug that has not been approved by the Food and Drug Administration. But he didn’t want to wait for the regulatory process to play out if he could take it sooner. Mr. Kalam is tapping into a thriving black market for retatrutide, a peptide medication developed by Eli Lilly. On social media, influencers and medical spas advertise the drug using code words like “ratatouille” for retatrutide or “peps” for peptides to skirt restrictions on advertising drugs online. More dedicated users buy in bulk from China, trading recommendations for sellers over conversations on Reddit, Discord and WhatsApp, and pooling their resources to get third-party testing. . . . . 😨🥶😷
- ·26.6.Unbelievable how it rises, and if it's pga the European Medicines Agency which has not approved it for cardiovascular diseases, then I soon don't know what, but rise it does, even on bad days
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt